171763-19-2

Basic information

• Product Name: 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine
• Synonyms: 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine
• CAS NO: 171763-19-2
• Molecular Weight: 478.62
• Mol File: 171763-19-2.mol
• Article Data: 53

Chemical Properties

• CAS DataBase Reference: 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine(171763-19-2)
• EPA Substance Registry System: 5'-O-tert-butyldiphenylsilyl-O²-2'-anhydro-5-methyluridine(171763-19-2)

Safety Data

• Hazardous Substances Data: 171763-19-2(Hazardous Substances Data)

Upstream product

• 1463-10-1 5-Methyluridine 
• 26879-47-0 1-(β-L-ribofuranosyl)thymine 
• 22423-26-3 O-2,2'-cyclo-5-methyluridine 
• 58479-61-1 tert-butylchlorodiphenylsilane 

Downstream Products

• 1244971-56-9 C₃₅H₄₀N₂O₉ 
• 1244973-39-4 C₄₄H₅₇N₄O₁₀P 
• 1244969-84-3 C₃₀H₄₀N₂O₇Si 
• 1244969-86-5 C₃₆H₄₄N₄O₁₀Si 
• 212061-24-0 5'-O-(tert-butyldiphenylsilyl)-2'-O-(2-hydroxyethyl)-5-methyluridine 
• 171762-75-7 1-[(2R,3R,4S,5S)-4-Allyl-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-hydroxy-tetrahydro-furan-2-yl]-3-benzyloxymethyl-5-methyl-1H-pyrimidine-2,4-dione 
• 171762-73-5 1-[(2R,3S,4S,5S)-4-Allyl-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-hydroxy-tetrahydro-furan-2-yl]-3-benzyloxymethyl-5-methyl-1H-pyrimidine-2,4-dione 
• 171762-81-5 C₅₅H₆₇N₅O₁₀Si₂ 
• 171762-83-7 C₄₄H₄₉N₅O₁₂ 
• 171762-74-6 Chloro-acetic acid (2R,3R,4R,5S)-4-allyl-2-(3-benzyloxymethyl-5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-5-(tert-butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-3-yl ester 
• 171762-77-9 3-Benzyloxymethyl-1-[(2R,3R,4R,5S)-5-(tert-butyl-diphenyl-silanyloxymethyl)-4-(2,3-dihydroxy-propyl)-3-methoxy-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 
• 171762-76-8 1-[(2R,3R,4R,5S)-4-Allyl-5-(tert-butyl-diphenyl-silanyloxymethyl)-3-methoxy-tetrahydro-furan-2-yl]-3-benzyloxymethyl-5-methyl-1H-pyrimidine-2,4-dione 
• 171762-80-4 [(2S,3R,4R,5R)-2-(tert-Butyl-diphenyl-silanyloxymethyl)-4-methoxy-5-(5-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-yl)-tetrahydro-furan-3-yl]-acetic acid 
• 171762-78-0 1-[(2R,3R,4R,5S)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-4-(2,3-dihydroxy-propyl)-3-methoxy-tetrahydro-furan-2-yl]-5-methyl-1H-pyrimidine-2,4-dione 

Relevant articles and documents

METHODS FOR THE PREVENTION AND TREATMENT OF MAJOR ADVERSE CARDIOVASCULAR EVENTS USING COMPOUNDS THAT MODULATE APOLIPOPROTEIN B

Provided herein, for example, are methods generally relating to preventing, treating and/or managing a major adverse cardiovascular event in a subject with a disease or condition at risk for a major adverse cardiovascular event, e.g., familial hypercholesterolemia. Also provided herein are methods relating to administering to the patient a therapeutically effective amount of an antisense oligonucleotide having a nucleobase SEQ ID NO: 247 (e.g., mipomersen).

Synthesis and antisense properties of 2′-O-(2S-methoxypropyl)-RNA- modified gapmer antisense oligonucleotides

To ascertain whether increasing hydrophobicity can enhance the activity of second-generation antisense oligonucleotides (ASOs) in muscle, we investigated the antisense properties of 2′-O-(2S-methoxypropyl)-RNA (2S-MOP)-modified ASOs. Synthesis of the 2S-MOP 5-methyl uridine phosphoramidite was accomplished on a multi-gram scale by Lewis-acid-catalyzed ring opening of 5′-O-tert-butyldiphenylsilyl ether-protected 2,2′-anhydro-5-methyl uridine with 2S-methoxy-1-propanol. Synthesis of the 2S-MOP 5-methyl cytidine nucleoside from the corresponding 5-methyl uridine nucleoside was accomplished by formation and displacement of a 4-triazolide intermediate with aqueous ammonia. 2S-MOP-modified oligonucleotides were prepared on an automated DNA synthesizer and showed similar enhancements in duplex thermal stability as 2′-O-methoxyethyl RNA (MOE)-modified oligonucleotides. 2S-MOP-containing antisense oligonucleotides were evaluated in Balb-c mice and showed good activity for decreasing the expression levels of scavenger receptor B1 (Srb1) and phosphatase and tensin homologue (PTEN) mRNA in liver and muscle tissue.

Antisense modulation of cyclin-dependent kinase 6 expression

Antisense compounds, compositions and methods are provided for modulating the expression of cyclin-dependent kinase 6. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acids encoding cyclin-dependent kinase 6. Methods of using these compounds for modulation of cyclin-dependent kinase 6 expression and for treatment of diseases associated with expression of cyclin-dependent kinase 6 are provided.